{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:55:10Z","timestamp":1781502910784,"version":"3.54.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Pyoderma gangrenosum is a rare autoimmune condition that is difficult to diagnose and primarily affects the skin. Extracutaneous manifestations, including hepatic involvement, occur only rarely. Here, we report a case of extracutaneous manifestation of pyoderma gangrenosum without adjunct skin lesions, emphasizing the diagnostic challenges, immunological considerations, and therapeutic implications. This case describes a 73-year-old man presenting with isolated hepatic and ocular involvement of pyoderma gangrenosum, without skin lesions and without an underlying chronic inflammatory disease. This case aims to expand the clinical understanding of the spectrum of pyoderma gangrenosum, reinforce its systemic nature, and contribute to improved recognition of extracutaneous disease involvement even without primary skin manifestation. The patient exhibited fever, weight loss of 3\u00a0kg within 3 weeks, elevated hepatocellular and cholestatic liver parameters (AST: 128 U\/L, upper limit norm [ULN]: 34 U\/L; ALT: 116 U\/L, ULN: 59 U\/L), and elevated CRP (147.5 mg\/L, ULN: 10 mg\/L). Imaging revealed disseminated nodular liver lesions. Histology demonstrated sterile abscesses and granulomatous inflammation. Ophthalmologic examination revealed conjunctival injections and granulomatous uveitis. No other organs were involved. Extensive testing excluded infectious or other immunological causes. After comprehensive screening for infectious, rheumatological, malignant, or hematological diseases, systemic inflammatory syndromes, and drug-induced liver injury, none of the suspected common diagnoses could be confirmed. In relation to the distinctive histological pattern resembling a few published case reports, we assumed pyoderma gangrenosum with hepatic and ocular involvement without skin lesions. We initiated immunosuppressive treatment with prednisone, followed by infliximab. This strategy successfully led to symptom resolution and complete clinical and biochemical remission. This case highlights the diagnostic challenges of granulomatous liver injury and pyoderma gangrenosum at unusual sites. Pyoderma gangrenosum is a rare condition, particularly when presenting with isolated hepatic and ocular involvement, and may be considered a differential diagnosis underlying granulomatous hepatic injury. Using a TNF-alpha inhibitor, we successfully achieved a complete remission.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1811910","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:33:59Z","timestamp":1781501639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor"],"prefix":"10.3389","volume":"17","author":[{"given":"Isabelle","family":"Panne","sequence":"first","affiliation":[{"name":"University Centre for Gastrointestinal and Liver Diseases, University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Matter","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrg","family":"Vosbeck","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"von Rotz","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Steinemann","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Hospital","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten","family":"Trendelenburg","sequence":"additional","affiliation":[{"name":"University Hospital Basel and Clinical Immunology, Department of Biomedicine, University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus H.","family":"Heim","sequence":"additional","affiliation":[{"name":"University Centre for Gastrointestinal and Liver Diseases, University Hospital","place":["Basel, Switzerland"]},{"name":"Departments of Biomedicine and Clinical Research, University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Heidelberg","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Gottardi","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Luzerner Kantonsspital","place":["Luzern, Switzerland"]},{"name":"Universit\u00e0 della Svizzera Italiana, Faculty of Biomedical Sciences","place":["Lugano, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Medical Centre Hamburg-Eppendorf","place":["Hamburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi M.","family":"Terracciano","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele","place":["Milan, Italy"]},{"name":"IRCCS Humanitas Research Hospital, Rozzano","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bernsmeier","sequence":"additional","affiliation":[{"name":"University Centre for Gastrointestinal and Liver Diseases, University Hospital","place":["Basel, Switzerland"]},{"name":"Departments of Biomedicine and Clinical Research, University of Basel","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41572-020-0213-x","article-title":"Pyoderma gangrenosum","volume":"6","author":"Maverakis","year":"2020","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2023.08.003","article-title":"Pyoderma gangrenosum","volume":"42","author":"Zaino","year":"2024","journal-title":"Dermatol Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(02)01165-X","article-title":"Ocular and extracutaneous involvement in pyoderma gangrenosum","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-015-0004-8","article-title":"Multiple abszesse nach s\u00fcdamerikakreuzfahrt","volume":"57","author":"Reynolds","year":"2016","journal-title":"Internist"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03055.x","article-title":"Pyoderma gangrenosum with liver, spleen and bone involvement in a patient with chronic myelomonocytic leukaemia","volume":"141","author":"Vadillo","year":"1999","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-019-01912-1","article-title":"Extracutaneous involvement of pyoderma gangrenosum","volume":"311","author":"Borda","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01168.x","article-title":"Pyoderma gangrenosum in a patient with myelodysplastic syndrome followed by possible extracutaneous manifestations in the gallbladder, liver, bone and lung","volume":"38","author":"Matsumura","year":"2011","journal-title":"J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.03055.x","article-title":"Pyoderma gangrenosum with liver, spleen and btone involvement in a patient with chronic myelomonocytic leukaemia","volume":"141","author":"Vadillo","year":"1999","journal-title":"Br J Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13838","article-title":"Association of pyoderma gangrenosum, erythema nodosum and aseptic liver abscess without significant underlying disease","volume":"44","author":"Hanami","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamadermatol.2017.5980","article-title":"Diagnostic criteria of ulcerative pyoderma gangrenosum: a delphi consensus of international experts","volume":"154","author":"Maverakis","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0251-7","article-title":"Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment","volume":"18","author":"Alavi","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/epidemiologia6030044","article-title":"Epidemiology, clinical data, and management of aseptic abscess syndrome: review of published cases outside France","volume":"6","author":"Eleftheriotis","year":"2025","journal-title":"Epidemiologia"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.13067","article-title":"Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: a semi\u2010systematic review","volume":"16","author":"Ben Abdallah","year":"2019","journal-title":"Int Wound J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf104","article-title":"Pyoderma gangrenosum with extracutaneous involvement: a systematic review","volume":"50","author":"Choe","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00281-025-01064-7","article-title":"Pyoderma gangrenosum: pathogenetic mechanisms and their implications for treatment","volume":"47","author":"Moltrasio","year":"2025","journal-title":"Semin Immunopathol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of pyoderma gangrenosum","volume":"42","author":"Tan","year":"2024","journal-title":"Dermatol Clin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16485","article-title":"Effectiveness of systemic treatments for pyoderma gangrenosum: a systematic review of observational studies and clinical trials","volume":"179","author":"Partridge","year":"2018","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond","year":"2023","journal-title":"Drugs"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15539","article-title":"Mycophenolate mofetil as adjunctive therapy to corticosteroids for the treatment of pyoderma gangrenosum: a case series and literature review","volume":"60","author":"Hrin","year":"2021","journal-title":"Int J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:34:01Z","timestamp":1781501641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":23,"alternative-id":["10.3389\/fimmu.2026.1811910"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1811910","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"article-number":"1811910"}}